sveSVENSKA   |   polPOLSKI   |   engENGLISH

+48 12 42 25 850 (Cracow) / +46 8 556 063 50 (Stockholm)     LinkedIN     Twitter

GAEU opens up new horizons - EUR 4,2 million for Immunovia from Horizon 2020!

GAEU opens up new horizons - EUR 4,2 million for Immunovia from Horizon 2020!

Date:
Tuesday, 24 March 2015

Another day, another success of GAEU Consulting in the largest ever R&D Programme in the European Union! Our team successfully applied for EUR 4,2 million of subsidy for the clinical validation of a ground-breaking biomarker for early diagnosis of pancreatic cancer. IMMUNOVIA AB (www.immunovia.se) is the recipient of funding under SME Instrument, Phase 2.

The project aims to perform the clinical validation of a serum biomarker signature for the diagnosis of pancreatic cancer. These clinical trials will lead to the final confirmation of biomarker’s efficacy in a non-symptomatic stage, when pancreatic cancer is still operable and curable. Nowadays, there is no method capable of identifying pancreatic cancer that early. Since the diagnosis is made to late, mortality rate of this malignancy is extremely high, and 5-year survivability – unprecedentedly low. The new biomarker will revolutionize the diagnosis of pancreatic cancer and patient management procedures on a global scale. The subsidy was granted under the Horizon 2020 Programme, SME Instrument, Topic: „Clinical research for the validation of biomarkers and/or diagnostic medical devices”.

The GAEU project team was responsible for finding and selecting the most suitable support measure under H2020, production of the grant application proposal in English, as well as ongoing advisory services for the Client.

Mats Grahn, CEO Immunovia:

"GAEU Consulting helped us structure our project based on the SME Instrument evaluation criteria. During the day-long workshop we discussed strategies and clinical content essential for a successful EU application. GAEU then wrote the EU application and methodically guided us through the application process. GAEU Consulting’s experts remained efficient and professional throughout the duration of the application process. They exemplified great levels of commitment and interest in our project. We are very pleased with GAEU’s efforts and highly recommend their services to other companies interested in Horizon 2020. GAEU Consulting is the excellent EU grant advisor for the excellent Horizon 2020 innovation project!"

Tomasz Wąsik, CEO GAEU Consulting Sp. z o.o.:

“GAEU’s success story in applying for funding from the Horizon 2020 Programme is not a coincidence, but a result of hard work and consistency in expanding the knowledge and expertise of our international team in production of R&D applications. We sincerely congratulate Immunovia this tremendous success. At the same time, we strongly encourage other entrepreneurs interested in obtaining some of the millions of euros available in the H2020 programme. We have both the knowledge and experience required for applying to the European Commission with a positive outcome.”

HORIZON 2020 PROGRAMME

Horizon 2020 is the largest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). The goal of the programme is to ensure that Europe produces world-class science technologies, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation. SMEs may apply for funding under special measure called SME Instrument.

PHASE I – ANALYSIS OF THE POTENTIAL FOR COMMERCIALIZATION

Phase 1 of the SME Instrument offers EUR 50 000 (70% of the eligible costs) for the analysis of technological concept of the project, evaluation of technical and commercial potential of the project, as well as risk assessment. The project should be realized within 6 months, leading to the elaboration of a feasibility study (including technical and commercial aspects) and a business plan, which will lay the foundation for applying to the next phase of the SME Instrument.

PHASE II – INNOVATION PROJECTS

In Phase 2 of the SME Instrument European companies may apply for funding of the projects aiming at development and demonstration of innovative products and technologies of high market potential. The European Commission expects that requested EU contribution of proposals will be in the range of EUR 0,5 to 2,5 million. The support intensity is 70% of the eligible costs (in special cases it may even reach 100%). Projects should last between 12 and 24 months.

 

Contact us for further information

Share with others